Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9706129 | 0.90 | ALDH1A3 (0.39) | MAPK1MEN1KMT2AALDH1A3 | |
| SCHEMBL3327499 | 0.82 | ALDH1A3 (0.34) | MAPK1MEN1KMT2AALDH1A3 | |
| SCHEMBL2246179 | 0.81 | ALDH1A3 (0.33) | MAPK1ALDH1A3 | |
| SCHEMBL10429856 | 0.80 | ADRA2A (0.43) | SLC6A4KDM4ELMNAGAAMAOA | |
| Hydrochloric Acid SCHEMBL9790311 | 0.79 | TDP1 (0.44) | TDP1MAPK1GAAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15412521 | 0.78 | ADRA2A (0.42) | SLC6A4KDM4ETDP1MAPK1LMNA | |
| SCHEMBL11625237 | 0.78 | ALDH1A3 (0.61) | KDM4ELMNAMEN1KMT2AMAPT | |
| SCHEMBL6788802 | 0.78 | LDHA (0.44) | LDHASLC6A4TDP1MAPK1LMNA | |
| SCHEMBL2224162 | 0.77 | PGR (0.30) | — | |
| SCHEMBL12130710 | 0.77 | HRH3 (0.44) | SLC6A4GAAMAOAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381718-B2 | Method for preparing oestrogen derivatives | AVENTIS PHARMA S.A. (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20040171595-A1 | Method for preparing oestrogen derivatives | AVENTIS PHARMA S.A. (FR) | 2004-09-02 | — | — | US | disclosed |
| US-4623660-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-18 | — | — | US | disclosed |
| US-4383998-A | Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1983-05-17 | — | — | US | disclosed |
| EP-0002097-B1 | TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171595-A1 | Method for preparing oestrogen derivatives | CYP19A1, HSD17B11, NR5A1 | LDHA 2561/4885SLC6A4 4353/4885KDM4E 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.